I explain exactly what this means for you further down
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
With no cutting, stitches, or downtime, it offers a gentler alternative that still provides high cure rates
Henry Johnson Rated 5 out of 5 Great delivery service and customer support
First introduced in Europe in the 1950s and approved by the U.S
In a phase 2 trial, once-weekly cagrilintide produced dose-dependent weight reductions in people with overweight or obesity, which is what moved the amylin pathway into serious combination development ( Lau et al., Lancet 2021 )